Actinium Pharmaceuticals signs R&D agreement with National Cancer Institute

Actinium Pharmaceuticals announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, part of the National Institutes for Health, to develop Actimab-A for the treatment of patients with acute myeloid leukemia and other hematologic malignancies. Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed. The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations, in line with Actinium’s strategy of leveraging Actimab-A’s targeted radiotherapy mechanism to elicit synergistic effects.